The Food and Drug Administration has approved a new first-line treatment option for adults and children aged 12 years and older with stage III or IV classical Hodgkin lymphoma. The combination therapy, which pairs the immunotherapy drug nivolumab (Opdivo) with standard chemotherapy—doxorubicin, vinblastine, and dacarbazine (AVD)—offers a significant advancement in treating this blood cancer, particularly for those who may not respond well to existing therapies.
This approval marks a shift in the treatment landscape for classical Hodgkin lymphoma, a cancer that originates in the lymphatic system. While often treatable, a subset of patients experience relapse or do not achieve remission with initial therapies. The new regimen provides a potentially more effective option, particularly given the results of the pivotal SWOG S1826 clinical trial.
Promising Results from the SWOG S1826 Trial
The FDA’s decision is based on data from the phase 3 SWOG S1826 trial, which involved 994 patients with advanced classical Hodgkin lymphoma. Researchers randomly assigned participants to receive either nivolumab in combination with AVD or brentuximab vedotin plus AVD. The trial, as previously reported, demonstrated a substantial benefit for those receiving the nivolumab-based regimen.
Specifically, the study found that adding nivolumab to AVD reduced the risk of disease progression or death by 58% compared to brentuximab vedotin plus AVD. This translates to a hazard ratio of 0.42 (95% confidence interval, 0.27-0.67), a statistically significant finding. After a median follow-up of 13.7 months, the nivolumab arm showed a clear advantage. Longer-term follow-up, with a median of 36.7 months, further solidified these findings, revealing fewer deaths in the nivolumab group (1.8% versus 3.4%).
Understanding Nivolumab and its Role in Cancer Treatment
Nivolumab is a type of immunotherapy called a checkpoint inhibitor. It works by blocking the PD-1 protein on immune cells, effectively releasing the brakes on the immune system and allowing it to recognize and attack cancer cells. The National Cancer Institute provides detailed information on checkpoint inhibitors and their mechanism of action.
Bristol Myers Squibb, the manufacturer of nivolumab (Opdivo), has been at the forefront of immunotherapy research. The drug has already received approvals for a variety of other cancers, including melanoma, lung cancer, and kidney cancer. Its application in Hodgkin lymphoma represents an expansion of its therapeutic potential.
Safety and Dosage Information
As with any cancer treatment, the nivolumab-AVD regimen is associated with potential side effects. In the SWOG S1826 trial, 39% of patients in the nivolumab arm experienced serious adverse reactions. Immune-mediated adverse events, where the immune system attacks healthy tissues, occurred in 9% of patients, with 2.7% experiencing grade 3 or 4 events—indicating severe or life-threatening complications.
The FDA-recommended dosage for nivolumab in this patient population is 240 mg administered intravenously for patients weighing 40 kg or more. For those weighing less than 40 kg, the dosage is 3 mg/kg. Treatment is given on days 1 and 15 of 28-day cycles, for a maximum of six cycles. Close monitoring for immune-mediated adverse events is crucial during treatment.
Expanded Approvals for Nivolumab in Hodgkin Lymphoma
Beyond this new first-line approval, the FDA also granted traditional approval for nivolumab in two additional settings for Hodgkin lymphoma. The drug is now approved for patients following autologous hematopoietic stem cell transplant and brentuximab vedotin, as well as for those who have progressed after three or more lines of systemic therapy, including a stem cell transplant. These indications had previously received accelerated approval, and the new data now support full approval.
This broader range of approved uses underscores the growing role of nivolumab in managing Hodgkin lymphoma across different stages and treatment histories. It provides clinicians with more options to tailor treatment plans to individual patient needs.
The approval of nivolumab in combination with chemotherapy represents a significant step forward in the treatment of classical Hodgkin lymphoma. Ongoing research will continue to refine treatment strategies and improve outcomes for patients facing this challenging cancer. Patients and their healthcare providers should discuss the potential benefits and risks of this new regimen to determine if it is the right option for their specific situation.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
Have questions or comments about this story? Share your thoughts below.
